Technical notes

EXPLORE OUR SCIENTIFIC RESOURCES

Contact an expert

Published on the 1 November 2018

Newsletter #3

New ETAP-Lab studies on TEMISIS’ drug candidate TEM1657 for Psoriasis ETAP-Lab performed new studies for the account of TEMISIS on a mouse imiquimod-induced psoriasis model. The output of thes…
Published on the 4 October 2018

Strok@lliance – Newsletter #4

Post-stroke deficits and recovery from bench to patient’s bed This year again, Strok@lliance aimed at bridging the gap between laboratory and clinical practices. The event occured at…
Published on the 1 October 2018

Newsletter #2

ETAP-Lab supports Plant Advanced Technologies in the development of its TEM1657 compound for the treatment of psoriasis TEM1657 is a drug candidate discovered and optimized by Plant Advanced Techno…
Published on the 22 May 2018

Strok@lliance – Newsletter #2

2nd Strok@lliance Annual Meeting June 5th, 2018 – 10:00 AM – 4:30 PMMAISON DE LA CHIMIE28 Rue Saint-Dominique, 75007 Parishttp://congres.maisondelachimie.com/ Post-stroke deficits and re…
Published on the 27 February 2018

Strok@lliance – Newsletter #1

Focus on an innovative model of thromboembolic stroke reproducing the clinical situation Recombinant tissue-type plasminogen activator (rt-PA) is the only approved drug treatment at the acute p…
Published on the 25 January 2018

Newsletter #1

New atopic dermatitis mouse model for in vivo efficacy studies Atopic dermatitis is a chronic allergic disease of the skin characterized by pruritus and eczematous skin lesions. It affects abou…